10:00 Fri 15 Jan 2021
Shield Therapeutics - Investor presentation
Shield Therapeutics plc
("Shield" or the "Group" or the "Company")
Investor presentation
No new material information will be disclosed at the event and the presentation will be made available on the Company website shortly after the events here: https://www.shieldtherapeutics.com/investors/presentations.
For further information please contact:
Shield Therapeutics plc |
|
|
+44 (0)20 7186 8500 |
|
+44 (0)19 1511 8500 |
Nominated Adviser and Joint Broker |
|
Peel Hunt LLP |
|
|
+44 (0)20 7418 8900 |
Joint Broker finnCap Ltd |
+44 (0)20 7220 0500 |
|
|
Financial PR & IR Advisor |
|
Walbrook PR |
+44 (0)20 7933 8780 or shield@walbrookpr.com |
Paul McManus/Lianne Cawthorne |
+44 (0)7980 541 893 / +44 (0)7584 391 303 |
|
|
About Shield Therapeutics plc
Shield is a de-risked, specialty pharmaceutical company focused on commercialising its lead product, Feraccru®/Accrufer®, a novel, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Feraccru®/Accrufer® has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. Feraccru® is commercialised in the UK and European Union by Norgine B.V. and the Company is currently in the process of evaluating commercialisation options for the US market, including the potential launch of Accrufer® in the US by Shield. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan.
For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE